jRCTb032210204招募中不适用
Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone marrow-derived mononuclear cells (TASSCAT-BM-MNC)
未提供0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 12
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 80age old not（—）
- 性别
- All
入选标准
- •Include patients who meet all of the selection criteria (1) to (8).
- •(1) Patients with a total of 9 or more ACR/EULAR systemic sclerosis criteria at the time of diagnosis, and who have been clinically diagnosed with systemic sclerosis by a physician.
- •(2) Patients who are at least 20 years old and under 80 years old at the time of obtaining written consent (irrespective of gender).
- •(3) Patients who have intractable skin ulcers associated with systemic sclerosis and whose ulcer area reduction rate is less than 20% during the 12-week observation period before registration.
- •(4) Patients who are judged to be inadequately effective after treatment for the past 12 weeks or more with a standard treatment approved by the public health insurance for skin ulcers associated with systemic sclerosis.
- •(5) Patients who have not performed split-thickness skin grafting or limb amputation for skin ulcer/gangrene.
- •(6) Patients holding limbs.
- •(7) Patients who have not been treated with therapeutic angiogenesis similar to this study.
- •(8) Patients who have given written informed consent to participate in the study.
排除标准
- •Subjects who do any of the following must not be included:
- •(1) Life expectancy is less than one year due to other complications.
- •(2) When there is a malignant tumor that has not been determined to be cured.
- •(3) If there is ischemic heart disease and blood circulation has not been reconstructed.
- •(4) If the HbA1c (NGSP) value within 10 days before registration is 10% or more, or if there is diabetic retinopathy.
- •(5) If there is an infection requiring systemic treatment or have a fever of 38.0 degrees C or more at the time of registration.
- •(6) If the laboratory test within 28 days before registration falls under the following or is a dialysis patient. a) AST: 100 U/L or more, b) ALT: 100 U/L or more, or c) eGFR: less than 25 mL/min/1.73m
- •(7) When there are severe blood diseases such as leukopenia and thrombocytopenia and severe anemia requiring blood transfusion.
- •(8) If patients are pregnant, nursing, may be pregnant or wish to become pregnant.
- •(9) Participation in clinical trials or clinical trials of drugs or medical devices within 28 days before registration in this study, and undergoing intervention such as test drugs.
- •(10) If there are other severe acute or chronic medical or mental conditions or abnormal laboratory values that may increase the risk of participating in the study or affect the interpretation of the study results.
- •(11) Patients who cannot escape amputation of the affected limb regardless of the success or failure of this treatment due to evidence of osteonecrosis or bone/tendon exposure in the ulcer/necrotic lesion before registration.
- •(12) Besides, when the chief investigator or the investigator judges that participation in this study is inappropriate.
结局指标
主要结局
-
Effective treatment rate
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Treatment of refractory ulcers with SimonkolleiteJPRN-jRCTs021210047orio Fukuda10
已完成
不适用
Treatment of cutaneous ulcer using platelet-rich plasmacutaneous ulcerJPRN-UMIN000009860ational Center for Global Health and Medicine20
已完成
不适用
Therapy of refractive skin ulcer by using platelet rich plasmadecubitus and refractive skin ulcer(excepting cosmetic surgery)JPRN-UMIN000023969St.Marianna University School of Medecine Dept. of Plastic and Reconstructive Surgery, Div. of Stem Cell Medecine23
招募中
不适用
Treatment of refractory ulcers with SimonkolleitejRCTs02121004710
暂停
不适用
PRP for intractable ulcersIntractable ulcersJPRN-jRCTc070190058Rikimaru Hideaki20